This week in therapeutics




Licensing status

Publication and contact information

Musculoskeletal disease

Bone repair

Not applicable

In vitro and mouse studies suggest depleting terminally differentiated CD8+ effector memory T cells could help prevent delayed fracture healing. In patients with delayed fracture healing, peripheral blood and fracture hematoma samples showed higher levels of terminally differentiated CD8+ effector memory T cells than samples from patients with normal fracture healing. In an osteogenic differentiation assay, cytokines produced by these CD8+ T cells decreased osteogenic differentiation and bone marrow mesenchymal stem cell viability compared with no treatment. In a mouse model for bone fracture, depletion of these CD8+ T cells improved fracture healing. Next steps include validation of these CD8+ T cells as a biomarker for delayed fracture healing.

SciBX 6(13); doi:10.1038/scibx.2013.315
Published online April 4, 2013

Patent application filed for diagnostic and therapeutic applications; available for licensing

Reinke, S. et al. Sci. Transl. Med.; published online March 20, 2013;
Contact: Hans-Dieter Volk, Charité-University Hospital Berlin, Berlin, Germany